[ad_1]
Pharmaceutical Pfizer Inc. said that an oral drug for treating COVID-19 could be available by end of 2021.
Soumyabrata Roy | NurPhoto | Getty Images
Pfizer on Tuesday reported first-quarter revenue and adjusted earnings that topped Wall Street’s expectations, despite a decline in sales driven by the lower demand for the company’s Covid vaccine.
Here’s what Pfizer reported compared with Wall Street’s expectations, based on a survey of analysts by Refinitiv:
- Earnings per share: $1.23 adjusted, vs. 98 cents expected
- Revenue: $18.28 billion, vs. $16.59 billion expected
The pharmaceutical giant posted net income of $5.54 billion, or 97 cents per share. That compares with $7.86 billion, or $1.37 per share, for the same period a year ago.
The Manhattan, New York-based company maintained its 2023 sales forecast of $67 to $71 billion guidance. Pfizer also reiterated its full-year adjusted earnings outlook of $3.25 to $3.45 per share.
Pfizer will hold an earnings call at 10:00 a.m. ET.
Read the earnings release.
This is a developing story. Check back for updates.
[ad_2]
